Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Conestat Alfa

            Therapeutic Area: Genetic Disease Product Name: Ruconest

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: NewBridge Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 20, 2021

            Details:

            Under the terms of the agreement, NewBridge will work closely with Pharming to provide access for RUCONEST® for the treatment of acute hereditary angioedema (“HAE”) in MENA.